Mortality is highest in patients with high-risk PCa, defined by the guidelines of the European Association of Urology (EAU) as T-stage ≥cT2c or Gleason score ≥8 or prostate-specific antigen (PSA) >20 ng/mL. The gene discussed is KLK3; the disease is posterior cortical atrophy.